Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding
Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity are being tested in clinical trials. Numerous rare variants of unknown clinical significance have been reported, but how the vast majori...
Gespeichert in:
| Veröffentlicht in: | Biochemical journal Jg. 479; H. 17; S. 1759 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
16.09.2022
|
| Schlagworte: | |
| ISSN: | 1470-8728, 1470-8728 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity are being tested in clinical trials. Numerous rare variants of unknown clinical significance have been reported, but how the vast majority impact on LRRK2 function is unknown. Here, we investigate 100 LRRK2 variants linked to PD, including previously described pathogenic mutations. We identify 23 LRRK2 variants that robustly stimulate kinase activity, including variants within the N-terminal non-catalytic regions (ARM (E334K, A419V), ANK (R767H), LRR (R1067Q, R1325Q)), as well as variants predicted to destabilize the ROC:CORB interface (ROC (A1442P, V1447M), CORA (R1628P) CORB (S1761R, L1795F)) and COR:COR dimer interface (CORB (R1728H/L)). Most activating variants decrease LRRK2 biomarker site phosphorylation (pSer935/pSer955/pSer973), consistent with the notion that the active kinase conformation blocks their phosphorylation. We conclude that the impact of variants on kinase activity is best evaluated by deploying a cellular assay of LRRK2-dependent Rab10 substrate phosphorylation, compared with a biochemical kinase assay, as only a minority of activating variants (CORB (Y1699C, R1728H/L, S1761R) and kinase (G2019S, I2020T, T2031S)), enhance in vitro kinase activity of immunoprecipitated LRRK2. Twelve variants including several that activate LRRK2 and have been linked to PD, suppress microtubule association in the presence of a Type I kinase inhibitor (ARM (M712V), LRR (R1320S), ROC (A1442P, K1468E, S1508R), CORA (A1589S), CORB (Y1699C, R1728H/L) and WD40 (R2143M, S2350I, G2385R)). Our findings will stimulate work to better understand the mechanisms by which variants impact biology and provide rationale for variant carrier inclusion or exclusion in ongoing and future LRRK2 inhibitor clinical trials. |
|---|---|
| AbstractList | Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity are being tested in clinical trials. Numerous rare variants of unknown clinical significance have been reported, but how the vast majority impact on LRRK2 function is unknown. Here, we investigate 100 LRRK2 variants linked to PD, including previously described pathogenic mutations. We identify 23 LRRK2 variants that robustly stimulate kinase activity, including variants within the N-terminal non-catalytic regions (ARM (E334K, A419V), ANK (R767H), LRR (R1067Q, R1325Q)), as well as variants predicted to destabilize the ROC:CORB interface (ROC (A1442P, V1447M), CORA (R1628P) CORB (S1761R, L1795F)) and COR:COR dimer interface (CORB (R1728H/L)). Most activating variants decrease LRRK2 biomarker site phosphorylation (pSer935/pSer955/pSer973), consistent with the notion that the active kinase conformation blocks their phosphorylation. We conclude that the impact of variants on kinase activity is best evaluated by deploying a cellular assay of LRRK2-dependent Rab10 substrate phosphorylation, compared with a biochemical kinase assay, as only a minority of activating variants (CORB (Y1699C, R1728H/L, S1761R) and kinase (G2019S, I2020T, T2031S)), enhance in vitro kinase activity of immunoprecipitated LRRK2. Twelve variants including several that activate LRRK2 and have been linked to PD, suppress microtubule association in the presence of a Type I kinase inhibitor (ARM (M712V), LRR (R1320S), ROC (A1442P, K1468E, S1508R), CORA (A1589S), CORB (Y1699C, R1728H/L) and WD40 (R2143M, S2350I, G2385R)). Our findings will stimulate work to better understand the mechanisms by which variants impact biology and provide rationale for variant carrier inclusion or exclusion in ongoing and future LRRK2 inhibitor clinical trials.Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity are being tested in clinical trials. Numerous rare variants of unknown clinical significance have been reported, but how the vast majority impact on LRRK2 function is unknown. Here, we investigate 100 LRRK2 variants linked to PD, including previously described pathogenic mutations. We identify 23 LRRK2 variants that robustly stimulate kinase activity, including variants within the N-terminal non-catalytic regions (ARM (E334K, A419V), ANK (R767H), LRR (R1067Q, R1325Q)), as well as variants predicted to destabilize the ROC:CORB interface (ROC (A1442P, V1447M), CORA (R1628P) CORB (S1761R, L1795F)) and COR:COR dimer interface (CORB (R1728H/L)). Most activating variants decrease LRRK2 biomarker site phosphorylation (pSer935/pSer955/pSer973), consistent with the notion that the active kinase conformation blocks their phosphorylation. We conclude that the impact of variants on kinase activity is best evaluated by deploying a cellular assay of LRRK2-dependent Rab10 substrate phosphorylation, compared with a biochemical kinase assay, as only a minority of activating variants (CORB (Y1699C, R1728H/L, S1761R) and kinase (G2019S, I2020T, T2031S)), enhance in vitro kinase activity of immunoprecipitated LRRK2. Twelve variants including several that activate LRRK2 and have been linked to PD, suppress microtubule association in the presence of a Type I kinase inhibitor (ARM (M712V), LRR (R1320S), ROC (A1442P, K1468E, S1508R), CORA (A1589S), CORB (Y1699C, R1728H/L) and WD40 (R2143M, S2350I, G2385R)). Our findings will stimulate work to better understand the mechanisms by which variants impact biology and provide rationale for variant carrier inclusion or exclusion in ongoing and future LRRK2 inhibitor clinical trials. Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity are being tested in clinical trials. Numerous rare variants of unknown clinical significance have been reported, but how the vast majority impact on LRRK2 function is unknown. Here, we investigate 100 LRRK2 variants linked to PD, including previously described pathogenic mutations. We identify 23 LRRK2 variants that robustly stimulate kinase activity, including variants within the N-terminal non-catalytic regions (ARM (E334K, A419V), ANK (R767H), LRR (R1067Q, R1325Q)), as well as variants predicted to destabilize the ROC:CORB interface (ROC (A1442P, V1447M), CORA (R1628P) CORB (S1761R, L1795F)) and COR:COR dimer interface (CORB (R1728H/L)). Most activating variants decrease LRRK2 biomarker site phosphorylation (pSer935/pSer955/pSer973), consistent with the notion that the active kinase conformation blocks their phosphorylation. We conclude that the impact of variants on kinase activity is best evaluated by deploying a cellular assay of LRRK2-dependent Rab10 substrate phosphorylation, compared with a biochemical kinase assay, as only a minority of activating variants (CORB (Y1699C, R1728H/L, S1761R) and kinase (G2019S, I2020T, T2031S)), enhance in vitro kinase activity of immunoprecipitated LRRK2. Twelve variants including several that activate LRRK2 and have been linked to PD, suppress microtubule association in the presence of a Type I kinase inhibitor (ARM (M712V), LRR (R1320S), ROC (A1442P, K1468E, S1508R), CORA (A1589S), CORB (Y1699C, R1728H/L) and WD40 (R2143M, S2350I, G2385R)). Our findings will stimulate work to better understand the mechanisms by which variants impact biology and provide rationale for variant carrier inclusion or exclusion in ongoing and future LRRK2 inhibitor clinical trials. |
| Author | Purlyte, Elena Padmanabhan, Shalini Sammler, Esther Alessi, Dario R Lange, Sven M Prescott, Alan R Wightman, Melanie Kalogeropulou, Alexia F Tonelli, Francesca |
| Author_xml | – sequence: 1 givenname: Alexia F surname: Kalogeropulou fullname: Kalogeropulou, Alexia F organization: Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, U.S.A – sequence: 2 givenname: Elena surname: Purlyte fullname: Purlyte, Elena organization: MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee, U.K – sequence: 3 givenname: Francesca surname: Tonelli fullname: Tonelli, Francesca organization: Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, U.S.A – sequence: 4 givenname: Sven M surname: Lange fullname: Lange, Sven M organization: MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee, U.K – sequence: 5 givenname: Melanie surname: Wightman fullname: Wightman, Melanie organization: MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee, U.K – sequence: 6 givenname: Alan R surname: Prescott fullname: Prescott, Alan R organization: Dundee Imaging Facility, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K – sequence: 7 givenname: Shalini surname: Padmanabhan fullname: Padmanabhan, Shalini organization: The Michael J. Fox Foundation for Parkinson's Research, New York, NY, U.S.A – sequence: 8 givenname: Esther surname: Sammler fullname: Sammler, Esther organization: Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, U.K – sequence: 9 givenname: Dario R orcidid: 0000-0002-2140-9185 surname: Alessi fullname: Alessi, Dario R organization: Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, U.S.A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35950872$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAYhC1URD9gYkfeYAm8fhMnzghVgUIlUAVz5MQ2Mk3sEieV-u8JokhM9-judMNNych5pwk5Z3DNIMGbu_kTAiKwlB2RCUsyiESGYvSPx2QawicASyCBEzKOec5hCCZEL5utrDrqDWUAdLVePyPdydZK1wVaW7fRinaevsp2Y13w7jJQZYOWQVPv6OD90LBgd7bbU-kUbWzV-q4v-1rT0jpl3ccpOTayDvrsoDPyfr94mz9Gq5eH5fx2FVVxiiwSQnKRcxQGVYLKMJbyXHKmUaaaZzwWAqDEXINRLEuTPFbcGJEqXsapESXOyNXv7rb1X70OXdHYUOm6lk77PhSYAWOxyCEfqheHal82WhXb1jay3Rd_1-A3d4dlCw |
| CitedBy_id | crossref_primary_10_1093_brain_awae188 crossref_primary_10_1002_mds_30284 crossref_primary_10_1177_1877718X251354986 crossref_primary_10_1038_s41467_024_52723_6 crossref_primary_10_1038_s41531_023_00608_8 crossref_primary_10_1038_s41531_025_01076_y crossref_primary_10_1002_mds_29449 crossref_primary_10_1007_s00401_025_02871_w crossref_primary_10_1038_s41588_024_01787_7 crossref_primary_10_7554_eLife_91083_4 crossref_primary_10_1016_j_jbc_2024_107469 crossref_primary_10_3389_fgene_2025_1579454 crossref_primary_10_1016_j_jmb_2023_168144 crossref_primary_10_1016_j_neuro_2024_06_016 crossref_primary_10_1038_s41531_025_00934_z crossref_primary_10_1042_BCJ20230126 crossref_primary_10_7554_eLife_94503_3 crossref_primary_10_1038_s41531_025_00896_2 crossref_primary_10_1016_j_parkreldis_2024_107024 crossref_primary_10_1073_pnas_2303789120 crossref_primary_10_1080_08927022_2024_2445645 crossref_primary_10_1101_cshperspect_a041774 crossref_primary_10_7554_eLife_91083 crossref_primary_10_3233_JPD_230376 crossref_primary_10_3390_biom13111645 crossref_primary_10_1016_j_nbd_2024_106571 crossref_primary_10_1126_science_adi9926 crossref_primary_10_1038_s41419_023_05964_0 crossref_primary_10_1083_jcb_202310150 crossref_primary_10_1002_jcb_70011 crossref_primary_10_1038_s41467_023_40532_2 crossref_primary_10_1016_j_celrep_2023_112447 crossref_primary_10_1016_j_celrep_2023_112448 crossref_primary_10_1016_j_parkreldis_2025_107299 crossref_primary_10_1038_s41531_025_00989_y crossref_primary_10_1134_S0026893325700025 crossref_primary_10_1016_j_jbc_2025_110376 crossref_primary_10_1073_pnas_2309698120 crossref_primary_10_3389_fneur_2022_1016040 crossref_primary_10_3390_biom13050845 crossref_primary_10_7554_eLife_94503 crossref_primary_10_1016_S1474_4422_22_00494_X crossref_primary_10_1007_s10048_025_00840_9 crossref_primary_10_1016_j_bioorg_2023_106972 crossref_primary_10_1038_s41467_025_62337_1 crossref_primary_10_1002_mds_29343 crossref_primary_10_1186_s13073_024_01335_2 crossref_primary_10_3389_fcell_2025_1569733 crossref_primary_10_1186_s40246_023_00499_z crossref_primary_10_1038_s43587_024_00760_7 crossref_primary_10_1038_s44319_025_00473_x crossref_primary_10_1002_mds_29385 crossref_primary_10_1016_j_gene_2023_147639 crossref_primary_10_1002_mdc3_70045 crossref_primary_10_1146_annurev_biochem_030122_051144 crossref_primary_10_3233_JPD_230432 crossref_primary_10_1038_s41582_023_00909_9 crossref_primary_10_1073_pnas_2412029122 crossref_primary_10_7554_eLife_87255 crossref_primary_10_1083_jcb_202307092 crossref_primary_10_1016_j_celrep_2025_116031 crossref_primary_10_1016_S1474_4422_24_00378_8 crossref_primary_10_1073_pnas_2421886122 crossref_primary_10_1038_s41531_023_00482_4 crossref_primary_10_1016_j_molmed_2024_07_003 crossref_primary_10_1042_BCJ20253099 crossref_primary_10_1042_BCJ20253133 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s). |
| Copyright_xml | – notice: 2022 The Author(s). |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1042/BCJ20220161 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry |
| EISSN | 1470-8728 |
| ExternalDocumentID | 35950872 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_12016/2 – fundername: Medical Research Council grantid: MC_UU_00018/1 – fundername: Chief Scientist Office grantid: SCAF/18/01 |
| GroupedDBID | --- -DZ -~X 0R~ 23N 2WC 4.4 53G 5GY 5RE 6J9 79B A8Z AABGO AAHRG ABJNI ABPPZ ABRJW ACGFO ACGFS ACNCT ADBBV AEGXH AENEX AIAGR AIZAD ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CS3 CUY CVF DU5 E3Z EBD EBS ECM EIF EMOBN F5P H13 HH6 HZ~ K-O L7B ML- MV1 N9A NPM NTEUP O9- OK1 P2P RHI RNS RPM RPO SV3 TR2 TWZ WH7 XSW Y6R YNY ~02 ~KM 7X8 ESTFP |
| ID | FETCH-LOGICAL-c3621-88a589528f2d42df11659a51e2a6e57538800b29e0fd176493d5ff86d5b36f8b2 |
| IEDL.DBID | 7X8 |
| ISSN | 1470-8728 |
| IngestDate | Thu Oct 02 04:43:35 EDT 2025 Sat May 31 02:12:08 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Keywords | leucine-rich repeat kinase Parkinson's disease signaling G-proteins |
| Language | English |
| License | 2022 The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3621-88a589528f2d42df11659a51e2a6e57538800b29e0fd176493d5ff86d5b36f8b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-2140-9185 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9472821 |
| PMID | 35950872 |
| PQID | 2701138909 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2701138909 pubmed_primary_35950872 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-16 |
| PublicationDateYYYYMMDD | 2022-09-16 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Biochemical journal |
| PublicationTitleAlternate | Biochem J |
| PublicationYear | 2022 |
| SSID | ssj0014040 |
| Score | 2.6307197 |
| Snippet | Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1759 |
| SubjectTerms | Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - metabolism Microtubules - metabolism Mutation Parkinson Disease - genetics Parkinson Disease - metabolism Phosphorylation Protein Binding |
| Title | Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35950872 https://www.proquest.com/docview/2701138909 |
| Volume | 479 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEA5eoC_e98EIok_FNG3T5EnWRfFcRBT2bUmbBARt1T3Af-9MtotPguBLKYVAmpnM_c0wdlQmSYqK0UQGbdkI9a2LirRII1vmspQSpbIPfWbv8k5Hdbv6oQm49ZuyyolMDILa1iXFyE9FjpyI2pXrs_ePiKZGUXa1GaExzWYTNGWIq_PuTxYh5WNAZJpzvPVCNfg85NPT8_aNIJBpLOPfbcugYy6X_ru7ZbbYWJfQGrPDCpty1Spba1XoWb99wTGEes8QSF9l8-3JrLc15q4DWBJqDzHncPf4eCtghG40VckAJXmdhUENhJEOcLGTPjSpHagrwG_0RhgJGkUBprLwRpV-g2ExfHVQvATszDp7vrx4al9FzQCGqES9FkdKmUzpTCgvbCqsp1Y92mSxE0Y6tPOokQwvhHbc2ziXqU5s5r2SNisS6VUhNthMVVdui0GWOCNwqUnQ4lFaanRrMqEtujNcaBNvs8PJwfbw3ylrYSpXD_u9n6PdZptj6vTex504eoQq5kjZnT-s3mULRHGq9YjlHpv1eL3dPpsrR4OX_udB4Bx8dh7uvwEAGct9 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+100+LRRK2+variants+linked+to+Parkinson%27s+disease+on+kinase+activity+and+microtubule+binding&rft.jtitle=Biochemical+journal&rft.au=Kalogeropulou%2C+Alexia+F&rft.au=Purlyte%2C+Elena&rft.au=Tonelli%2C+Francesca&rft.au=Lange%2C+Sven+M&rft.date=2022-09-16&rft.eissn=1470-8728&rft.volume=479&rft.issue=17&rft.spage=1759&rft_id=info:doi/10.1042%2FBCJ20220161&rft_id=info%3Apmid%2F35950872&rft_id=info%3Apmid%2F35950872&rft.externalDocID=35950872 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-8728&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-8728&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-8728&client=summon |